Genedrive MT-RNR1 ID Kit to detect genetic variation and protect hearing in babies: early value appraisal.
The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.
Recent Posts
Simponi Pediatric Approval: FDA Grants First Pediatric Indication for Ulcerative Colitis Treatment
The U.S. Food and Drug Administration has granted Simponi pediatric approval for Johnson & Johnson's Simponi (golimumab), which is intended for children with moderately to severely active ulcerative colitis who weigh at least 15 kg. This historic approval is backed by data from the PURSUIT pr...
Paving the Way for Digital Health Technologies: NICE’s Bold New Strategy for the NHS
The National Institute for Health and Care Excellence (NICE) is expanding its technology appraisals programme, and starting April 2026, this will include digital health technologies that are placed on an equal legal footing with medicines in the NHS. This initiative forms part of the NHS 10-year ...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse
The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...